Immunological profile of the tumor immune microenvironment of upper tract urothelial carcinoma predicts recurrence patterns

上尿路尿路上皮癌肿瘤免疫微环境的免疫学特征可预测复发模式

阅读:3
作者:Kenta Takahashi #,Daiki Ikarashi #,Shigehisa Kitano #,Daichi Tamura,Masakazu Abe,Ayato Ito,Ei Shiomi,Shigekatsu Maekawa,Renpei Kato,Mitsugu Kanehira,Naoki Yanagawa,Wataru Obara #

Abstract

Background: The association between the tumor immune microenvironment (TiME) in upper tract urothelial carcinoma (UTUC) and its prognosis remains unclear. We investigated the relationship between TiME and UTUC recurrence patterns. Methods: We evaluated 90 patients who underwent nephroureterectomy for UTUC and divided them into nonrecurrence, distant metastasis, and intravesical recurrence-only groups. We assessed the association of the TiME with clinicopathological factors using surgical tissues and the prognosis of the three groups via multiplex fluorescence immunohistochemistry. Results: The median age was 71 years (44-89), and 58 (64%) were male. Intratumoral CD4+ T cell density was significantly higher in the nonrecurrence group (p = 0.0004) than the other groups, whereas intra- and peritumoral regulatory T cell (Treg; CD3+CD4+FoxP3+ cell) density was higher in the distant metastases group than the intravesical recurrence-only group (p = 0.0025). In the multivariate analysis, pathological T stage and CD4+ T cells, and pathological T stage and Treg were independent predictors of recurrence-free survival (p = 0.045, p = 0.017) and metastatic-free survival (p = 0.027, p = 0.011), respectively. Conclusions: Our study demonstrated that CD4+ T cells and Tregs in the TiME of patients with UTUC were independent predictors of high-risk recurrence together with high pathological stage. The analysis of TiME in surgical specimens may provide an objective indicator of the efficacy of adjuvant therapy in UTUC.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。